Study wrapper · #993
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Vahle B, Weidner S, Tomalka A, et al. Circulation. Heart failure. 2026.
DOI: 10.1161/circheartfailure.126.014397PubMed: 42290373
Editor's note
A controlled rat study showing SS-31 improving skeletal-muscle function in a HFpEF model, with a plausible cardiolipin-stabilization mechanism. Evidence remains preclinical and animal-only.
Plain-language abstract
In a rat model of heart failure with preserved ejection fraction, elamipretide (SS-31) improved skeletal-muscle force and reduced muscle atrophy, apparently by stabilizing cardiolipin.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Trends in pharmacological sciencesn=——2026